German law introduced in 2011 that requires new medicines to undergo an early benefit assessment to determine whether they provide added value over existing treatments, which then forms the basis for price negotiations in Germany.
German law introduced in 2011 that requires new medicines to undergo an early benefit assessment to determine whether they provide added value over existing treatments, which then forms the basis for price negotiations in Germany.